<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26272" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Oral Melanoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brizuela</surname>
            <given-names>Melina</given-names>
          </name>
          <aff>International University Of Catalunya (UIC)</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mazzoni</surname>
            <given-names>Thomas</given-names>
          </name>
          <aff>Cooperman Barnabas Medical Center/Rutgers University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Melina Brizuela declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Mazzoni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26272.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Oral melanoma is a very rare malignancy that progresses rapidly and proves to be particularly aggressive. The clinical aspect of oral melanoma is varied. Still, it usually presents as a black-brown patch, macule, or nodular lesion with different shades of grey, red, purple, or areas of depigmentation. This activity reviews the etiology, pathophysiology, epidemiology, history and physical evaluation, and diagnosis of oral melanoma, with its differential diagnosis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the current knowledge regarding the etiology and pathophysiology of oral melanoma.</p></list-item><list-item><p>Describe the history and physical evaluation, and histopathology of oral melanoma.</p></list-item><list-item><p>Outline the differential diagnosis of oral melanoma.</p></list-item><list-item><p>Summarize the management options for oral melanoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26272&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26272">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26272.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Oral melanoma is a very rare malignancy that progresses rapidly and proves to be&#x000a0;particularly aggressive. This lesion accounts for 0.2% to 8% of all melanomas<xref ref-type="bibr" rid="article-26272.r1">[1]</xref>&#x000a0;and 1% to 2% of all oral malignancies.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Compared with other melanomas, mucosal melanomas have the lowest percentage of 5-year survival rate, likely due to delayed detection.<xref ref-type="bibr" rid="article-26272.r3">[3]</xref><xref ref-type="bibr" rid="article-26272.r4">[4]</xref><xref ref-type="bibr" rid="article-26272.r5">[5]</xref><xref ref-type="bibr" rid="article-26272.r6">[6]</xref>&#x000a0;The clinical aspect of oral melanoma is varied. Still, it usually presents as a black-brown patch, macule, or nodular lesion with different shades of grey, red, purple, or areas of depigmentation.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;Amelanotic lesions have also been reported.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;The etiology, risk factors, and pathophysiology are still&#x000a0;poorly understood.&#x000a0;Biopsy remains the gold standard for diagnosing oral melanomas,<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;and radical surgical excision is the treatment of choice.&#x000a0;Additional treatment modalities include radiotherapy, chemotherapy, and immunotherapy.</p>
      </sec>
      <sec id="article-26272.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology, risk factors, and pathogenesis of oral melanoma remain poorly understood. Unlike&#x000a0;its skin counterpart, it is not related to sun exposure as the oral mucosa&#x000a0;is protected from ultraviolet light.<xref ref-type="bibr" rid="article-26272.r8">[8]</xref>&#x000a0;Primary oral mucosa melanomas mainly&#x000a0;originate de novo, but up to 37% are preceded by pigmented lesions, lasting for months to years.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;Denture irritation, infection, and tobacco smoking have been listed as possible risk factors, but a&#x000a0;direct relationship is not substantiated.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
      </sec>
      <sec id="article-26272.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Oral melanoma is a very rare and aggressive&#x000a0;carcinoma&#x000a0;that accounts for 0.2% to 8% of all melanomas&#x000a0;<xref ref-type="bibr" rid="article-26272.r1">[1]</xref>&#x000a0;and 1% to 2% of all oral malignancies.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Interestingly, unlike its skin counterpart, its incidence remained steady over the last years.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref></p>
        <p>Oral melanoma prevalence increases with age.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;It develops between the 4th and 7th decade of life,&#x000a0;<xref ref-type="bibr" rid="article-26272.r1">[1]</xref>&#x000a0;with an average age of 60.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref> The gender difference is not significant; some studies report female predominance, others male prevalence,&#x000a0;or do not report any discrepancy.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Regarding ethnicity, oral melanoma is uncommon in white individuals&#x000a0;<xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;and more frequent in Japanese,<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;black, and Indian populations.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
      </sec>
      <sec id="article-26272.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Melanoma develops from a malignant transformation of melanocytes. Even though the exact pathophysiology of mucosal melanomas is yet to be determined,&#x000a0;some pathways have been identified.</p>
        <p>
<bold>Mutations in c-KIT</bold>
</p>
        <p>Recent data indicates that c-KIT (CD117) is overexpressed in many mucosal melanoma cases. This pathway is important and common in acral and mucosal melanoma, melanomas unrelated to sun exposure.<xref ref-type="bibr" rid="article-26272.r9">[9]</xref>&#x000a0;KIT is a transmembrane tyrosine kinase receptor expressed on hematopoietic progenitor cells, melanocytes, mast cells, primordial germ cells, and interstitial cells of Cajal.&#x000a0;Activating mutations and amplifications cause activation of growth and proliferation pathways. Drugs that work on the tyrosine kinase activities, such as imatinib, show some promise in treating mucosal melanomas expressing the c-kit protein, but treatment failure has also been reported.<xref ref-type="bibr" rid="article-26272.r9">[9]</xref></p>
        <p>
<bold>Mutations in BRAF</bold>
</p>
        <p>Bioinformatics Resources and Applications Facility (BRAF) protein mutations are uncommon in mucosal melanoma and found in less than 10% of cases. However, in cutaneous melanoma, BRAF mutations are found in up to 80% of cases. Dabrafenib and vemurafenib are used for patients exhibiting BRAF mutation-positive melanoma.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
      </sec>
      <sec id="article-26272.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The anatomy of the mouth differs from the skin. Due to the lack of histological landmarks analogous to the papillary, reticular dermis, and muscle bundles, a pathological leveling system, and description cannot be appropriately applied for mucosal melanomas. Therefore, Clark&#x02019;s levels, commonly used in cutaneous melanoma, cannot be implemented. Many melanomas in the mouth have a histologic similarity with lentigo maligna melanoma in a radial growth phase.&#x000a0;</p>
        <p>Mucosal melanomas can show three principal patterns. An in situ melanoma is in the epithelium and does not cross the epithelial-connective tissue interface.<xref ref-type="bibr" rid="article-26272.r10">[10]</xref>&#x000a0;A deeply invasive or nodular melanoma extends to the underlying connective tissue. A combined pattern is characterized by an in situ or radially growing pattern combined with a nodular component.<xref ref-type="bibr" rid="article-26272.r10">[10]</xref></p>
        <p>The characteristic histopathological features of mucosal melanomas include atypical melanocytes (hyperchromatism and nuclear pleomorphism) in the epithelium and connective tissue junction. This, combined with positive S-100 and HMB-45 markers, is confirmatory of mucosal melanoma.<xref ref-type="bibr" rid="article-26272.r11">[11]</xref></p>
        <p>Approximately 15% of cases of oral melanoma are in situ mucosal lesions, 30% of cases are invasive lesions, and 55% of cases have a combined pattern of invasive with in situ components. Most advanced lesions have a combination pattern of invasive melanoma with an in situ component.</p>
        <p>
<bold>Immunohistochemistry</bold>
</p>
        <p>Although not specific, S-100 and HMB-45 are helpful markers that are positive in almost all oral melanomas (94%).<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Fatty acid synthase (FASN) can help to differentiate oral melanomas from oral melanocytic nevi since this marker is strongly expressed in melanomas of the mucosal surfaces.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
      </sec>
      <sec id="article-26272.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Oral melanomas show an aggressive nature and worse prognosis than cutaneous melanoma. Almost a third of patients already&#x000a0;have signs of lymph node metastasis at the moment of diagnosis,<xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;probably because this malignancy goes unnoticed due to a lack of symptoms in the early stages.<xref ref-type="bibr" rid="article-26272.r12">[12]</xref> Pain, bleeding, and ulceration are&#x000a0;uncommon until late in the disease.</p>
        <p>Primary oral melanomas&#x000a0;have a strong preference for the maxilla, mainly developing in the hard palate, gingiva, or alveolar ridge.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref><xref ref-type="bibr" rid="article-26272.r1">[1]</xref><bold>&#x000a0;</bold>Secondary oral melanomas (even rarer than primary tumors) commonly&#x000a0;occur in the&#x000a0;tongue.<xref ref-type="bibr" rid="article-26272.r1">[1]</xref>&#x000a0;Most oral melanomas arise de novo in an apparently normal oral mucosa, but up to a third are preceded by melanosis.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;This&#x000a0;pigmented area is&#x000a0;believed to represent the radial expansion phase before the deep invasion of the underlying tissue.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
        <p>The clinical aspect of oral melanomas is indeed diverse. They can&#x000a0;present as macules, patches, or nodules, showing various colors: brown, black, grey, red, or purple shades and even depigmentation.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref> The lesions are asymmetric, with an irregular outline, and can be sometimes multiple.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Satellite foci surrounding the tumor have been reported.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref><xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;Up to a third of oral melanomas are ulcerated.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref></p>
        <p>The most typical presentation comprises three particular features: a) a&#x000a0;brown-black pigmented plaque that is flat or slightly raised, b) a light brown macular feature, and c) a central area of nodular aspect.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref><xref ref-type="bibr" rid="article-26272.r13">[13]</xref></p>
        <p>Amelanotic&#x000a0;melanomas are not uncommon, accounting for around a third of oral melanomas.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;These lesions pose a diagnostic challenge since they may be misdiagnosed as benign tumors, like epulis, or as squamous cell carcinoma.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
      </sec>
      <sec id="article-26272.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Early diagnosis is essential since&#x000a0;oral melanomas show a very aggressive evolution with a poor prognosis. However, there are still no criteria to aid the diagnosis in the oral cavity.&#x000a0;Clinical examination can be supported by dermoscopy,&#x000a0;but the complex oral mucosa anatomy and irregular surface represent a technical limitation.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;Biopsy remains the gold standard to diagnose oral melanomas. Incisional biopsy from the thickest part of a large lesion and excisional biopsy of small lesions are indicated.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Ultrasound or CT scan of the head and neck and thoracoabdominal regions is required to stage the tumor correctly.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref></p>
        <p>
<bold>Dermoscopy</bold>
</p>
        <p>The most common dermoscopic features include diffuse and irregular pigmentation with pseudo-network, regression structures, and a blue-white veil.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Other&#x000a0;characteristics are asymmetrical structures, irregular margins, and the abrupt interruption of the reticular pattern.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;Atypical vessels, dots, and globules can also be seen.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref></p>
      </sec>
      <sec id="article-26272.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Surgery is the mainstay of treatment in oral malignant melanoma.<xref ref-type="bibr" rid="article-26272.r11">[11]</xref> Radical excision with disease-free margins is the first goal in surgical management.&#x000a0;Adjuvant therapy includes radiation, chemotherapy, and immunotherapy.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
        <p>Even though melanoma is classically non-radiosensitive,<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;some authors have seen improvement after&#x000a0;radiotherapy, especially better local control and survival.<xref ref-type="bibr" rid="article-26272.r11">[11]</xref></p>
        <p>Chemotherapy with platinum analog, nitrosoureas,&#x000a0;dacarbazine, and immunotherapy with IL-2 have shown low response.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Metastatic melanomas with a c-kit mutation have benefited from imatinib therapy.<xref ref-type="bibr" rid="article-26272.r9">[9]</xref>&#x000a0;Dabrafenib and vemurafenib are used for patients exhibiting a positive BRAF mutation melanoma.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
      </sec>
      <sec id="article-26272.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of oral melanoma is extensive; it needs to be differentiated from focal and diffuse oral pigmentations. Amalgam tattoos&#x000a0;most commonly mimic oral melanomas, and dermoscopy may aid in differentiating them.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref></p>
        <p>The following are included in the differential diagnosis of an oral melanoma:<xref ref-type="bibr" rid="article-26272.r7">[7]</xref></p>
        <p>
<bold>Focal Oral Pigmentations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amalgam tattoo (exogenous pigment)</p>
          </list-item>
          <list-item>
            <p>Melanoacanthoma</p>
          </list-item>
          <list-item>
            <p>Melanotic macules</p>
          </list-item>
          <list-item>
            <p>Melanocytic nevi</p>
          </list-item>
        </list>
        <p>
<bold>Diffuse Oral Pigmentations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Physiological/racial pigmentations</p>
          </list-item>
          <list-item>
            <p>Smoker&#x02019;s melanosis</p>
          </list-item>
          <list-item>
            <p>Drug-induced hyperpigmentation</p>
          </list-item>
          <list-item>
            <p>Postinflammatory hyperpigmentation</p>
          </list-item>
        </list>
        <p>
<bold>Systemic Diseases</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Peutz&#x02013;Jeghers syndrome</p>
          </list-item>
          <list-item>
            <p>Laugier&#x02013;Hunzikerdisease</p>
          </list-item>
          <list-item>
            <p>Leopard syndrome</p>
          </list-item>
          <list-item>
            <p>Carney complex syndrome</p>
          </list-item>
          <list-item>
            <p>McCune-Albright syndrome</p>
          </list-item>
          <list-item>
            <p>Adrenal gland diseases</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26272.s11" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Tumor, T</bold>
<xref ref-type="bibr" rid="article-26272.r14">[14]</xref>
</p>
        <p>There is no T1 or T2 in mucosal melanoma.</p>
        <list list-type="bullet">
          <list-item>
            <p>T3: Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or non-pigmented lesions of the oral cavity, pharynx, or larynx</p>
          </list-item>
          <list-item>
            <p>T4: Moderately advanced or very advanced</p>
          </list-item>
          <list-item>
            <p>T4a: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin</p>
          </list-item>
          <list-item>
            <p>T4b: Very advanced disease. Tumor involving the brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures</p>
          </list-item>
        </list>
        <p>
<bold>Lymph Nodes, N</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>NX: Regional lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p>N0: No regional lymph node metastases</p>
          </list-item>
          <list-item>
            <p>N1: Regional lymph node metastases present</p>
          </list-item>
        </list>
        <p>
<bold>Distant Metastases, M</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>M0: No distance metastasis</p>
          </list-item>
          <list-item>
            <p>M1: Distant metastasis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26272.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with oral melanomas are often diagnosed at an advanced stage of the disease and have a very poor prognosis.<xref ref-type="bibr" rid="article-26272.r15">[15]</xref>&#x000a0;The five-year survival rate is 25,5% for mucosal melanomas&#x000a0;in the head and neck.<xref ref-type="bibr" rid="article-26272.r2">[2]</xref>&#x000a0;Around&#x000a0;a third of patients present lymph node metastasis at the moment of diagnosis.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref> This is believed to be partly because the region is highly vascularized and also due to&#x000a0;its lymphatic drainage anatomy.<xref ref-type="bibr" rid="article-26272.r7">[7]</xref>&#x000a0;The expression of bcl-2&#x000a0;is linked to a better prognosis of mucosal melanomas.<xref ref-type="bibr" rid="article-26272.r16">[16]</xref>&#x000a0;Aberrant expression of p53 protein and loss of expression of p16 protein are associated with a poor prognosis.<xref ref-type="bibr" rid="article-26272.r16">[16]</xref></p>
        <p>After complete surgical excision, relapse rates have been reported to be&#x000a0;about 20%.<xref ref-type="bibr" rid="article-26272.r11">[11]</xref> Recurrence has been noted even up to 11 years following surgery.&#x000a0;Metastases in the lymph nodes of the neck, lungs, liver, and brain can be seen.</p>
      </sec>
      <sec id="article-26272.s13" sec-type="Complications">
        <title>Complications</title>
        <p>The complications are related to the surgical excision of the melanoma, including loss of tissue, prolonged healing, grafting, and prothesis need. Also, xerostomia, candidiasis, and hypernasal speech are side effects of the surgery.</p>
      </sec>
      <sec id="article-26272.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Depending on complications and distant metastases, consultations with otolaryngology (head and neck surgery), surgical oncology, oral and maxillofacial surgery, oral pathology, speech therapy, and other specialties&#x000a0;are warranted.</p>
      </sec>
      <sec id="article-26272.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Early recognition and treatment&#x000a0;of&#x000a0;oral mucosal melanomas significantly improve the prognosis. Preventive strategies are unknown, but some experts suggest educating patients on regular oral self-examination to help identify early suspicious pigmented or non-pigmented lesions.</p>
        <p>An appropriate self-examination requires a mouth mirror, standard mirror, and good lightning.&#x000a0;Patients should also be instructed to grab their tongue with the help of gauze&#x000a0;for a better view of the oral tissues.</p>
        <p>Due to the high risk of recurrence, patients with a history of oral melanoma require lifelong follow-up.</p>
      </sec>
      <sec id="article-26272.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Primary mucosal melanomas are aggressive tumors that are exceedingly rare but rapidly lethal.&#x000a0;This disease is particularly hard to treat because it is usually discovered at an advanced stage.&#x000a0;Dentists have a unique opportunity to diagnose this lesion promptly and improve the patient&#x02019;s prognosis. Other healthcare professionals, including dermatologists and general practitioners, should add an oral examination to their regular appointments and be familiar with the aspect of this carcinoma.&#x000a0;Asymptomatic irregular melanotic lesions should raise concern and be further investigated,<xref ref-type="bibr" rid="article-26272.r11">[11]</xref> especially those in sites most common to oral melanoma.</p>
        <p>Patients need should be instructed to implement&#x000a0;self-examinations for early detection. Trained primary care nurses&#x000a0;can educate the patient in this regard. They also need to inform the patient on what constitutes a high-risk lesion and communicate these findings to the clinician as soon as they arise. Despite the low incidence of oral melanoma, a collaborative interprofessional team can help reduce morbidity and mortality associated with it. [Level 5]</p>
      </sec>
      <sec id="article-26272.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26272&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26272">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/oral-melanoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26272">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26272/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26272">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26272.s18">
        <title>References</title>
        <ref id="article-26272.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aguas</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Quarracino</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lence</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Lanfranchi-Tizeira</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Primary melanoma of the oral cavity: ten cases and review of 177 cases from literature.</article-title>
            <source>Med Oral Patol Oral Cir Bucal</source>
            <year>2009</year>
            <month>Jun</month>
            <day>01</day>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>E265</fpage>
            <page-range>E265-71</page-range>
            <pub-id pub-id-type="pmid">19300378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warszawik-Hendzel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>S&#x00142;owi&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olszewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rudnicka</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management.</article-title>
            <source>J Dermatol Case Rep</source>
            <year>2014</year>
            <month>Sep</month>
            <day>30</day>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>60</fpage>
            <page-range>60-6</page-range>
            <pub-id pub-id-type="pmid">25324906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <collab>PDQ Pediatric Treatment Editorial Board</collab>
            <chapter-title>Rare Cancers of Childhood Treatment (PDQ&#x000ae;): Health Professional Version</chapter-title>
            <source>PDQ Cancer Information Summaries [Internet]</source>
            <publisher-name>National Cancer Institute (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>9</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">26389315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Besra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Samantaray</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pathy</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Rout</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological study of malignant melanoma in a regional cancer center.</article-title>
            <source>Indian J Cancer</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>292</fpage>
            <page-range>292-296</page-range>
            <pub-id pub-id-type="pmid">30693897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Natarajan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Black and Brown Oro-facial Mucocutaneous Neoplasms.</article-title>
            <source>Head Neck Pathol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-70</page-range>
            <pub-id pub-id-type="pmid">30693458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Yook</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Loss of SLC25A11 causes suppression of NSCLC and melanoma tumor formation.</article-title>
            <source>EBioMedicine</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>40</volume>
            <fpage>184</fpage>
            <page-range>184-197</page-range>
            <pub-id pub-id-type="pmid">30686754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambertini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patrizi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Melotti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Caliceti</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Magnoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Misciali</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baraldi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ravaioli</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Dika</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Oral melanoma and other pigmentations: when to biopsy?</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-214</page-range>
            <pub-id pub-id-type="pmid">28862771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Jungbluth</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoshaw-Woodard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Busam</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck.</article-title>
            <source>Head Neck</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>1053</fpage>
            <page-range>1053-7</page-range>
            <pub-id pub-id-type="pmid">15515159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivera</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Nagatsuka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gunduz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cengiz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gunduz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siar</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tsujigiwa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tamamura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma.</article-title>
            <source>Virchows Arch</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>452</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-32</page-range>
            <pub-id pub-id-type="pmid">18066592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barker</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Leider</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lozada-Nur</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Melrose</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merrell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Regezi</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Rick</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Rohrer</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Slater</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tomich</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Oral mucosal melanomas: the WESTOP Banff workshop proceedings. Western Society of Teachers of Oral Pathology.</article-title>
            <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>83</volume>
            <issue>6</issue>
            <fpage>672</fpage>
            <page-range>672-9</page-range>
            <pub-id pub-id-type="pmid">9195622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misra</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Oral malignant melanoma: a rarity!</article-title>
            <source>BMJ Case Rep</source>
            <year>2021</year>
            <month>Nov</month>
            <day>11</day>
            <volume>14</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34764097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumari</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral Malignant Melanoma: A Case Report.</article-title>
            <source>Prague Med Rep</source>
            <year>2021</year>
            <volume>122</volume>
            <issue>3</issue>
            <fpage>222</fpage>
            <page-range>222-227</page-range>
            <pub-id pub-id-type="pmid">34606435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komatsubara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shigeta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ojima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Minamikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shibuya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yokoo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Komori</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Treatment and prognosis of malignant melanoma of the oral cavity: preoperative surgical procedure increases risk of distant metastasis.</article-title>
            <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>106</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-7</page-range>
            <pub-id pub-id-type="pmid">18504155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aloua</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaouani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerdoud</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Salissou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Slimani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Melanoma of the oral cavity: A silent killer.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>62</volume>
            <fpage>182</fpage>
            <page-range>182-185</page-range>
            <pub-id pub-id-type="pmid">33532067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hicks</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Flaitz</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Oral mucosal melanoma: epidemiology and pathobiology.</article-title>
            <source>Oral Oncol</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-69</page-range>
            <pub-id pub-id-type="pmid">10745167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26272.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hoshaw-Woodard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Busam</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.</article-title>
            <source>Head Neck Pathol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>184</fpage>
            <page-range>184-90</page-range>
            <pub-id pub-id-type="pmid">22160615</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
